EJMK Ventures LLC Buys Shares of 5,667 Merck & Co., Inc. $MRK

EJMK Ventures LLC acquired a new position in shares of Merck & Co., Inc. (NYSE:MRK) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 5,667 shares of the company’s stock, valued at approximately $596,000.

A number of other institutional investors have also recently bought and sold shares of the company. Kingdom Financial Group LLC. purchased a new stake in shares of Merck & Co., Inc. during the 4th quarter worth about $25,000. Abound Financial LLC bought a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at approximately $26,000. Prosperity Bancshares Inc acquired a new position in Merck & Co., Inc. in the fourth quarter worth approximately $26,000. United Financial Planning Group LLC acquired a new position in Merck & Co., Inc. in the third quarter worth approximately $31,000. Finally, High Note Wealth LLC raised its position in Merck & Co., Inc. by 58.9% during the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after acquiring an additional 109 shares in the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Analyst Ratings Changes

MRK has been the subject of a number of analyst reports. Royal Bank Of Canada reiterated an “outperform” rating and issued a $142.00 target price on shares of Merck & Co., Inc. in a research note on Monday, March 30th. Wells Fargo & Company cut their price target on shares of Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Weiss Ratings lowered shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 15th. UBS Group upped their price objective on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Monday, April 13th. Finally, Wall Street Zen raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research report on Saturday, June 6th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $128.18.

Merck & Co., Inc. Trading Up 0.1%

NYSE:MRK opened at $114.04 on Friday. Merck & Co., Inc. has a 12 month low of $76.66 and a 12 month high of $125.14. The firm has a market cap of $281.65 billion, a price-to-earnings ratio of 32.12, a P/E/G ratio of 2.56 and a beta of 0.21. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. The company’s 50 day moving average is $115.94 and its 200-day moving average is $113.60.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. During the same period in the prior year, the firm earned $2.22 EPS. Merck & Co., Inc.’s quarterly revenue was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Equities analysts anticipate that Merck & Co., Inc. will post 5.17 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th will be given a $0.85 dividend. This represents a $3.40 annualized dividend and a dividend yield of 3.0%. The ex-dividend date of this dividend is Monday, June 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 95.77%.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.